Nightstar Therapeutics plc [●] American Depositary Shares Representing [●] Ordinary Shares (Nominal Value £0.01 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT by and amongDeposit Agreement • April 3rd, 2018 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of September 27, 2017, by and among (i) NIGHTSTAR THERAPEUTICS PLC, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
DEPOSIT AGREEMENT by and among NIGHTSTAR THERAPEUTICS PLC And CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of September 27, 2017Deposit Agreement • October 18th, 2017 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of September 27, 2017, by and among (i) NIGHTSTAR THERAPEUTICS PLC, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2019 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), dated and entered into as of the 20th day of October, 2017 (“Effective Date”), by and between Nightstar, Inc., a Delaware corporation and wholly owned subsidiary of Nightstar Therapeutics plc, a company incorporated under the laws of England and Wales (hereinafter referred to together as the “Company”), and Gregory Robinson (the “Employee”).
ContractLicensing Agreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
ContractNon-Exclusive Patent License Agreement • August 28th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
IMPLEMENTATION AGREEMENT Skadden, Arps, Slate, Meagher & Flom (UK) LLP 40 Bank Street Canary Wharf London E14 5DSImplementation Agreement • March 4th, 2019 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances)
NIGHTSTARX LIMITED EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2019 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
AGREEMENT, dated and entered into as of the 1st day of June, 2017 (“Effective Date”), by and between NightstaRx Limited, a company registered in England and Wales (the “Company”), and Tuyen Ong, (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2019 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
This EMPLOYMENT AGREEMENT (the "Agreement"), dated and entered into as of the 29th day of September, 2017 ("Effective Date"), by and between Nightstar, Inc., a Delaware corporation and wholly owned subsidiary of Nightstar Therapeutics Limited, a company incorporated under the laws of England and Wales (hereinafter referred to together as the "Company"), and Seokho Bryan Yoon (the "Employee").
DATED 12th October 2017Licence of Technology • April 3rd, 2018 • Nightstar Therapeutics PLC • Biological products, (no disgnostic substances)
• Licensee is a private biopharmaceutical company focused on the development of therapies for inherited retinal dystrophies.
